Carbachol

FDA label, Alcon Laboratories, Inc., ophthalmic, effective 2023-02-10. Full label on DailyMed

Patient handout

Looking up MedlinePlus…

From MedlinePlus, U.S. National Library of Medicine

Quoted from the FDA label. Product labels differ by manufacturer and change over time; confirm against the label for the product you are using.

Dosing in kidney impairment

This label has no separate kidney-impairment dosing section. Check warnings and clinical pharmacology in the full label.

Contraindications

CONTRAINDICATIONS: Should not be used in those persons showing hypersensitivity to any of the components of this preparation.

Pregnancy and lactation

Pregnancy

Pregnancy: There are no adequate and well-controlled studies in pregnant women. MIOSTAT* (carbachol intraocular solution, USP) 0.01% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Lactation

Nursing Mothers: It is not known if this medication is excreted in breast milk. Exercise caution when administering to a nursing woman.

For breastfeeding, also see LactMed (National Library of Medicine), which summarizes milk levels and infant effects.

Supply and cost

Drug shortage status

Loading
Source: FDA Drug Shortages Database via openFDA

Recalls (last 24 months)

Loading
Source: FDA Enforcement Reports via openFDAFDA recalls and safety alerts

Therapeutic equivalence (Orange Book)

Loading
Source: FDA Orange Book data filesSearch the Orange Book

Price ladder

Not the price at the counter
Loading

These are not what a patient pays at the pharmacy counter. They are what pharmacies, health plans, and government buyers pay, before manufacturer rebates. A patient's cost depends on their insurance (copay, coinsurance, or deductible) or the pharmacy's cash price.

VA Federal Supply ScheduleCMS NADACMedicare Part D plan filesMedicaid State Drug Utilization Data

Products and NDCs

Loading